Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. Academic Article uri icon

Overview

abstract

  • Here, we present an update of a phase 2 study of pembrolizumab in patients with advanced thymic carcinoma who failed previous therapies. Duration of response was approximately 3 years, and median survival was in excess of 2 years with a 5-year survival rate of 18%. The higher than expected incidence of severe autoimmune disorders (15%) did not substantially increase with a longer follow-up. Pembrolizumab induces durable responses in patients with thymic carcinoma. Careful selection of patients and monitoring of toxicities are warranted.

publication date

  • November 25, 2020

Research

keywords

  • Antineoplastic Agents, Immunological
  • Lung Neoplasms
  • Thymoma
  • Thymus Neoplasms

Identity

Scopus Document Identifier

  • 85097790410

Digital Object Identifier (DOI)

  • 10.1016/j.jtho.2020.11.003

PubMed ID

  • 33248322

Additional Document Info

volume

  • 16

issue

  • 3